Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Jan;123(1):e121-6.
doi: 10.1542/peds.2008-0176.

Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents

Stephen M Arpadi  1 , Donald McMahon, Elaine J Abrams, Marukh Bamji, Murli Purswani, Ellen S Engelson, Mary Horlick, Elizabeth Shane
Affiliations
Randomized Controlled Trial

Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents

Stephen M Arpadi et al. Pediatrics. 2009 Jan.

Erratum in

  • Pediatrics. 2009 May;123(5):1437

Abstract

Objective: Vitamin D insufficiency occurs commonly in HIV-infected youth in the United States. In light of the importance of vitamin D for skeletal and nonskeletal health, including innate immunity, developing methods for improving vitamin D status in HIV-infected children and adolescents is an important area of clinical research. The objective of this study was to evaluate the effect of administration of oral cholecalciferol, 100,000 IU every 2 months, and 1 g/day calcium on serum 25-hydroxyvitamin D concentrations, serum and urine calcium, and HIV disease progression during a 12-month period.

Methods: HIV-infected children and adolescents who were aged 6 to 16 years were randomly assigned to receive vitamin D (100,000 IU bimonthly) and calcium (1 g/day; n = 29) or double placebo (n = 27). Serum 25-hydroxyvitamin D concentrations as measured by radioimmunoassay, albumin-corrected calcium concentrations, and spot urinary calcium-creatinine ratios were determined monthly.

Results: No abnormalities in serum calcium concentration were observed. One participant who received placebo developed hypercalciuria. No group differences were seen in the change in CD4 count or CD4% or viral load during 12 months. The overall mean monthly serum 25-hydroxyvitamin D concentrations were higher in the group that received vitamin D and calcium than in the placebo group, as was the monthly serum 25-hydroxyvitamin D area under the curve. After completing 12 months of study, 2 (6.7%) participants in the group that received vitamin D and calcium had a trough serum 25-hydroxyvitamin D concentration <20 ng/mL compared with 14 (50%) in the placebo group. Twelve (44.4%) in the group that received vitamin D and calcium had a trough serum 25-hydroxyvitamin D concentration of > or =30 ng/mL compared with 3 (11.1%) in the placebo group.

Conclusions: Administration of oral cholecalciferol to HIV-infected children and adolescents at a dosage of 100,000 IU every 2 months, together with 1 g/day calcium, is safe and results in significant increases in serum 25-hydroxyvitamin D concentrations.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Study participant flow.
FIGURE 2
FIGURE 2
Mean monthly serum 25-OHD ± SEM in HIV-infected children who received bimonthly oral cholecalciferol 100 000 IU (solid line; n = 29) or double placebo (dashed line; n = 27).
See this image and copyright information in PMC

References

    1. Stephensen CB, Maquis GS, Kruzich LA, Douglas SD, Altrovandi GM, Wilson CM. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr. 2006;83(5):1135–1141. - PubMed
    1. United States Pharmacopeia. Rockville, MD: United States Pharmacopeial Convention, Inc; 2002.
    1. Marshall WA, Tanner JM. Variations in patterns of pubertal changes in boys. Arch Dis Child. 1970;45(239):13–23. - PMC - PubMed
    1. Marshall WA, Tanner JM. Variations in patterns of pubertal changes in girls. Arch Dis Child. 1969;44(235):291–303. - PMC - PubMed
    1. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep. 1994;43(RR-12):1–19.

Publication types